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The Ninth Meeting on Human Genome Variation and
Complex Genome Analysis was held in Sitges, Spain, in
September 2007. This annual meeting, which originally focused
on single nucleotide polymorphisms (SNPs), broadened its scope
from 2006 onward to encompass the entire range of genomic
variability. Maintaining the relatively small format of 200
delegates, the meeting gathered leading investigators in copy
number variation (CNV), SNP association studies, ultrasequen-
cing, population genetics, statistical analysis, and database
management, as well as young investigators who initiated careers
in these fields. The two-and-a-half-day meeting combined
sponsorship by several academic institutions and corporate entities
in a venue that facilitated interaction and communication between
the participants.
The Sitges venue was particularly conducive to the formal and
informal discussions that have long characterized this meeting.
These discussions were wide-ranging, and while they often began
in the meeting rooms, they usually continued through meals and
into the evening.
A key focus was the question of how to facilitate the continued
success of genome-wide association studies (GWAS). It has been
widely appreciated that large-scale collaboration has been hugely
beneficial to early GWAS, and there was considerable discussion
at the meeting of the need to establish and maintain the
bioinformatics infrastructure necessary to make maximum use of
the data being generated. While initial efforts toward building such
infrastructure in the United States and Europe have made
impressive inroads in serving both data and results of GWAS
(summarized by a number of the participants—see below), the
need for richer resources allowing integration of GWAS across
more phenotypes, including expression phenotypes from multiple
human tissues, was apparent. Such resources would allow more
rapid and broad-based assessment of functional relationships
among genetic variations (SNP and CNV), expression phenotypes,
disease states, and related quantitative traits. There was also
widespread sentiment that larger samples sizes, while clearly
desirable, would, in the end, provide only a fraction of the
contribution of genetic variation to complex disorders. Advances
in analytic approaches coupling statistical genetics with bioinfor-
matics may prove to be fruitful in extending results of GWAS.
There was vigorous discussion of the likely contribution of
structural variation to human genetic disease. Although a number
of participants confirmed the contribution of CNVs to various
human disorders, known CNVs are highly skewed toward the
lower end of the minor allele frequency spectrum. This skewing
was thought to reflect an initial bias toward detection of larger
CNVs; a discovery bias which precludes a comprehensive
understanding of the contribution of this class of genetic variants
to human disease and reduces the likelihood of being able to
reliably ‘‘tag’’ CNVs even if most were the consequence of a single
(rather than recurrent) events. As technology improvements allow
detection of smaller CNVs that may have a higher minor allele
frequency as well as more precise delineation of the exact
sequences involved, we will not only get a more accurate picture
of the contribution of these variants to disease but also gain
insights into the dynamics, the evolutionary history, and the
consequences of such variants. A key question is whether such sites
are generally uniquely created, with a single originating event, or
rather are commonly regenerated, due perhaps to the presence of
repetitive elements. This will determine whether such variants can
be tagged and indirectly interrogated (e.g., through imputation) or
will need to be directly interrogated, which will in turn influence
the design of later generation platforms for GWAS.
Technology, particularly the newest sequencing technologies,
was also a major topic of discussion. A number of new approaches
as well as more streamlined versions of existing technologies were
discussed. The meeting certainly highlighted the steady steps
toward the eventual goal of sequencing entire human genomes at
reasonable financial cost and with efficient computational
algorithms.
Abstracts of the meeting and an expanded version of the
meeting report can be found on the meeting Web sites (http://
hgv2007.nci.nih.gov; http://www.tcag.ca/hgv2008) and in Text
S1 (abstracts) and Text S2 (meeting report).
Highlights of the presentations include the considerable progress
reported by Stephen Chanock and colleagues at the National
Cancer Institute (Bethesda, Maryland, United States) in recent
months on the identification of genetic variants that predispose to
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approach used in GWAS followed by meta-analysis on data from
several other groups. Xavier Estivill (Center for Genomic
Regulation, Barcelona, Spain) reported a common genomic
feature of disorders for which CNVs have been detected, namely
the presence of segmental duplications in the vicinity. Moreover,
all CNV loci that have been found associated with common
disorders are both complex and multi-allelic, making it difficult to
tag these CNVs with SNPs. Pui-Yan Kwok (University of
California San Francisco, California, United States) sounded a
cautionary note regarding quality control of genotype data in the
context of automated genotype data production.
In the area of sequencing the individual genome, one of the
most challenging problems is the assembly of the sequences and
the large number of differences between sequences, including
many structural variation changes. Samuel Levy (J. Craig Venter
Institute, Rockville, Maryland, United States) reported the details
of the sequencing, assembly, and variant detection in the genome
of Craig Venter. Using newly developed genome assembly
strategies and comparative genome-to-genome mapping methods,
they identified 25 Mb of diploid sequence differences, representing
more than 4 million DNA variants, thereby increasing the
estimate of DNA sequence differences between unrelated humans
to 5–10 times more than previously thought. Sanjeev Bhaskar
(Wellcome Trust Sanger Institute, Hinxton, United King) and Ivo
Gut (Centre National de Ge ´notypage, Evry Cedex, France)
described their efforts in high-throughput, targeted sequencing
using a variety of approaches. George Church (Harvard Medical
School and Massachusetts Institute of Technology, Boston,
Massachusetts, United States) showed that 1% of the genome
harboring most causative alleles for medical and nonmedical traits
could be targeted for sequencing using strategies he and others
have developed. He pointed out that by combining these
approaches with paired-end tags for rearrangements (such as
those described by Jan Korbel at Yale University, New Haven,
Connecticut, United States) and allele-specific RNA quantifica-
tion, an affordable analysis of the human genome could be
achieved at the individual level.
The intensity of CNV research was evident in the presentations
of several groups at the HGV2007 meeting. For example, Steve
Scherer (Hospital for Sick Children, Toronto, Ontario, Canada)
reported the recent findings on chromosome rearrangements and
imbalances in autism spectrum disorders, with evidence showing
that chromosome rearrangements in autism are likely to be
involved in 10%–20% of all cases. Barbara Trask (Fred
Hutchinson Cancer Research Center, Seattle, Washington,
United States) reported on the important role CNVs played in
the evolution of three families of chemosensory receptors (olfactory
receptors and two classes of vomeronasal receptors [V1Rs and
V2Rs]) that help an organism interact with its environment.
George Perry and Charles Lee (Brigham and Women’s
Hospital, Boston, Massachusetts, United States) presented data
about the distribution of amylase gene (AMY1) copies in different
populations that showed a positive or directional selection on
AMY1 copy number in human populations with diets high in
starch but neutral evolution on AMY1 copy number in low-starch
populations. Joris Veltman (Radboud University Nijmegen
Medical Centre, Nijmegen, The Netherlands) presented the use
of dense bacterial artificial chromosome (BAC) arrays and SNP
arrays to identify CNVs underlying mental retardation. The use of
parallel approaches and data sharing by investigators from
different countries has allowed them to identify new syndromes
that were previously unrecognized. Matthew Hurles (The
Wellcome Trust Sanger Institute, Hinxton, United Kingdom)
reported on the use of ultrasequencing technologies to identify and
characterize structural variation. He also presented data on the
development of a comprehensive map for common CNVs using
high-density oligonucleotide arrays with 42 million probes across
the genome. Finally, he stressed the need for improved methods
for CNV genotyping and quantification to deal with multiallelic
CNVs and with differential biases in assessing CNVs in cases and
controls. To facilitate the precise quantification of copy numbers
of particular genes in subjects, John Armour (University of
Nottingham, Nottingham, United Kingdom) described the
development of paralogue ratio tests (PRTs) that improve the
precision, economy, and throughput for complex CNV genotyp-
ing.
Combining CNV and SNP data in GWAS is a major challenge
for statistical geneticists, and a number of groups presented
strategies to tackle this problem. Nancy Cox (University of
Chicago, Chicago, Illinois, United States) reviewed general
approaches for direct and indirect assessment of CNV information
to study common disorders. She reported on the use of TUNA
(Testing Untyped Alleles) to utilize linkage disequilibrium (LD) to
interrogate CNVs for which multilocus LD tags can be
constructed. Don Conrad (University of Chicago, Chicago,
Illinois, United States) described new methodology for integrating
CNVs into the study of genetic traits. Iuliana Ionita (Harvard
University, Boston, Massachusetts, United States) reported on the
development of an extension of a family-based association test
(FBAT) approach to analyze CNV data with family-based designs.
Vivian Cheung (University of Pennsylvania, Philadelphia,
Pennsylvania, United States) reported on research to identify
genetic variation affecting interindividual gene expression. Of
3,500 genes with variable expression levels, 235 were associated
with SNPs (80% in trans,5 %i ncis, and 15% with multiple effects)
in a GWAS. Manolis Dermitzakis (Wellcome Trust Sanger
Institute, Hinxton, United Kingdom presented data on the
widespread genetic variation in mRNA levels of many genes
across populations. Moreover, many detected associations between
gene expression levels and SNPs are shared across human
populations, and that signal is concentrated, within 100 kb from
the promoter, symmetrically around transcription start sites.
Chris Ponting (University of Oxford, Oxford, United
Kingdom) discussed the elevated density of genes, evolutionary
rates, and gene functions, noting data consistent with the
possibility that some of these regions have been positively selected
in the human population due to advantageous gene dosage effects
of copy number variants. Jaume Bertranpetit (Pompeu Fabra
University, Barcelona, Spain) discussed the possibilities of
computing population recombination rates from SNP frequency
data. They found that most of the variation is among major
human groups and a minor component of population variation is
within continents, with most recombination hotspots conserved
among human populations. Esteban Gonza ´lez-Burchard
(University of California San Francisco, San Francisco, California,
United States) provided fundamental evidence of genetic differ-
ences between racial and ethnic populations relevant to differences
in genetic risk for Alzheimer disease and HIV resistance. Gilles
Thomas (National Cancer Institute, Bethesda, Maryland, United
States) presented data on population stratification in two genome-
wide studies in breast cancer and prostate cancer. Their results
showed evidence of population structure on the European
continent and pointed to the need to correct for population
stratification in searching for association in European populations.
In addition to the GWAS approach, Angel Carracedo
(University of Santiago de Compostela, Galicia, Spain) discussed
classical approaches to identifying genetic variations associated
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the current applications in clinical practice and the changes in
labeling that have been recommended by the regulatory agencies
in Europe and United States (European Medicines Agency
[EMEA] and Food and Drug Administration [FDA], respectively)
for about ten drugs).
Another important topic of discussion at the meeting was the
current status and future needs for central genomic databases in
the area of human variation. Yum Lina Yip (Swiss Institute of
Bioinformatics, Geneva, Switzerland) gave a presentation on
archiving single amino acid polymorphisms in the UniProt/Swiss-
Prot knowledge base, with .30,000 single amino acid polymor-
phisms (SAPs) in about 6,000 human proteins already archived
and many more to come. Andrew Devereau (National Genetics
Reference Laboratory, Manchester, United Kingdom) reported on
the use of a variation database for diagnostic molecular
laboratories. This tool allows data from different laboratories
and different sources to be integrated and analyzed for the
interpretation of its clinical significance. Anthony Brookes
(University of Leicester, Leicester, United Kingdom) presented
progress toward developing HGVbaseG2P, a database of
genotype-to-phenotype (G2P) relationships, which aims to pull
together a comprehensive view of the world’s genetic association
study findings. He also described GEN2PHEN (http://www.
gen2phen.org/), a European Commission Integrated Project
designed to help provide globally relevant solutions for G2P
databasing. Ewan Birney (European Bioinformatics Institute,
Hinxton, United Kingdom) presented an overview of the Ensembl
infrastructures for genomic information, from its storage through
to analysis and visualization. The data included variation
information for more than 6,000 human individuals and
resequencing data from six. James Ostell (National Library of
Medicine, Bethesda, Maryland, United States) described several of
the resources of the National Center for Biotechnology Informa-
tion (NCBI), including the Database of Genotype and Phenotype
(dbGaP), which holds phenotype data from long-term clinical and
cohort studies, and is linked to large-scale genotype results on the
participants or to medical sequencing data in support of GWAS.
Lincoln Stein (Cold Spring Harbor Laboratory, Cold Spring
Harbor, New York, United States) presented the new features and
tools of the HapMap Web site and discussed progress toward
providing views of resequencing data, particularly as it moves
toward sequencing entire human genomes. Carole Charlier
(University of Lie `ge, Wallonia, Belgium) reported on the use of
Patrocles, a database of polymorphic miRNA-mediated gene
regulation that assists in the identification of SNPs that affect such
regulation. Lars Feuk (The Hospital for Sick Children, Toronto,
Ontario, Canada) described the latest version of the Database of
Genomic Variants, which contains all the published CNVs in the
genome. This database faces the challenges of definition of CNV
boundaries, detection of false positives, and determination of
accurate population frequency information.
The meeting also devoted discussion to the ethical aspects of
individualized sequencing. Anne Cambon-Thomsen (Inserm
and University Paul Sabatier Toulouse III, Toulouse, France)
reviewed the issue of human biobanks for studying human genome
variation. She reported on the networking of biobanks (Public
Population Project in Genomics, http://www.p3gconsortium.org/;
European Biobanks, http://www.biobanks.eu/) and described some
of the conflicting interests that have to be balanced, such as
participant privacy, potential risks and benefits, methodological
guidance for interpretation and use of data, professional recognition
of investigators, sharing of samples and data, intellectual property
rights, and characteristics of a centralized data repository or other
repository.
The Sitges meeting also included more than 150 posters
presented over the three-day meeting. The prevailing view was
that each attendee left the meeting with new ideas in a field that is
moving rapidly at the cutting edge of discovery of the genetic
variants that will define disease predisposition and help to uncover
new biological pathways for understanding human health and
disease. The HGV2008 meeting (http://www.tcag.ca/hgv2008/)
will be held 15–17 October 2008, in Toronto, Canada. That
meeting will focus, in part, on further steps for the sequencing and
resequencing of the human genome.
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